Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT02485015

The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

The Randomized, Controlled, Multicenter Clinical Trial of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

Sponsor: The First People's Hospital of Changzhou

Conditions Stomach Neoplasms

Interventions Apatinib Cytokine-Induced Killer Cells

Updated 5 times since 2017 Last updated: Feb 18, 2016 Started: Jun 30, 2015 Primary completion: Jun 30, 2030 Completion: Jun 30, 2033

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Stomach Neoplasms, this trial is ongoing. The trial is conducted by The First People's Hospital of Changzhou and has accumulated 5 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Jan 2021 — Jul 2024 [monthly]

Active Not Recruiting PHASE2
Jun 2018 — Jan 2021 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2

First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The First People's Hospital of Changzhou

Data source: The First People's Hospital of Changzhou

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.